Technical Analysis for ACOR - Acorda Therapeutics, Inc.
|Grade||Last Price||% Change||$ Change|
ACOR closed unchanged on Tuesday, February 21, 2017, on 86 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Trend Table & Recent Alerts
|Weak or Absent||Up||Up||Up|
|See historical ACOR trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 17||NR7||Range Contraction||0.00%|
|Feb 17||Calm After Storm||Range Contraction||0.00%|
|Feb 16||Stochastic Reached Overbought||Other||0.00%|
|Feb 16||Calm After Storm||Range Contraction||0.00%|
|Feb 15||Spinning Top||Other||-0.39%|
|Feb 15||Calm After Storm||Range Contraction||-0.39%|
|Feb 14||Calm After Storm||Range Contraction||6.08%|
|Feb 13||Stochastic Reached Overbought||Other||3.69%|
|Feb 13||Slingshot Bullish||Bullish Swing Setup||3.69%|
|Feb 13||Calm After Storm||Range Contraction||3.69%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
- Earnings date: 2017-02-14
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACOR news...
|52 Week High||37.36|
|52 Week Low||16.4|
|200-Day Moving Average||23.1|
|50-Day Moving Average||21.08|
|20-Day Moving Average||22.47|
|10-Day Moving Average||24.06|
|Average True Range||1.23|
|Chandelier Exit (Long, 3 ATRs)||22.46|
|Chandelier Exit (Short, 3 ATRs)||22.99|
|Upper Bollinger Band||26.56|
|Lower Bollinger Band||18.38|
|Percent B (%b)||0.85|